[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
August 25, 2004

Promising SARS Vaccine

JAMA. 2004;292(8):916. doi:10.1001/jama.292.8.916-b

Scientists have developed an experimental nasal spray vaccine that may protect individuals from severe acute respiratory syndrome (SARS) virus infection if another outbreak should occur (Lancet. 2004;363:2122-2127). Researchers from the National Institute of Allergy and Infectious Diseases, in Bethesda, Md, designed the vaccine by creating a recombinant attenuated parainfluenza virus that expresses the SARS envelope spike protein. (This strain of virus is being developed as a live attenuated intranasal pediatric vaccine against human parainfluenza virus type 3.) The spike protein is a viral surface protein used by the SARS virus to invade human cells.

First Page Preview View Large
First page PDF preview
First page PDF preview
×